Results 131 to 140 of about 1,601 (193)
Some of the next articles are maybe not open access.
Seminars in Thrombosis and Hemostasis, 2023
Among the tests that study the presence of circulating antiphospholipid ...
M. Monti +7 more
semanticscholar +1 more source
Among the tests that study the presence of circulating antiphospholipid ...
M. Monti +7 more
semanticscholar +1 more source
Cefazolin-induced hypoprothrombinemia
American Journal of Health-System Pharmacy, 2008A case of cefazolin-induced hypoprothrombinemia in a patient with renal failure is reported.A 50-year-old African-American woman was transferred from the orthopedics service to the internal medicine service for management of acute renal failure. Before her transfer, she had spinal surgery and subsequently developed a wound infection complicated by ...
Amy H, Chung, Kristin, Watson
openaire +2 more sources
Lupus, 2023
Objective Children with lupus anticoagulant hypoprothrombinemia syndrome (LAHPS) are characterized by prolonged activated partial thromboplastin time (APTT) and prothrombin time (PT), lupus anticoagulant positivity and low prothrombin (factor II, FII ...
Yanhong Sun +3 more
semanticscholar +1 more source
Objective Children with lupus anticoagulant hypoprothrombinemia syndrome (LAHPS) are characterized by prolonged activated partial thromboplastin time (APTT) and prothrombin time (PT), lupus anticoagulant positivity and low prothrombin (factor II, FII ...
Yanhong Sun +3 more
semanticscholar +1 more source
Hypoprothrombinemia in Naproxen Overdose
Drug Intelligence & Clinical Pharmacy, 1983Transient prolongation of the prothrombin time was observed in the setting of a 10-g overdose of naproxen. The patient reported was previously healthy, without chronic liver disease, bleeding disorders, or malnutrition. The most likely mechanism for this effect is direct inhibition of the synthesis of vitamin-K-dependent clotting factors, possibly via
P K, Waugh, D W, Keatinge
openaire +2 more sources
The American Journal of Medicine, 1987
A 66-year-old man with the lupus anticoagulant-hypoprothrombinemia syndrome was treated with cyclophosphamide and prednisone to correct a factor II deficiency prior to elective major surgery. Whereas the lupus anticoagulant activity persisted, functional factor II levels normalized and he underwent surgery without a bleeding diathesis ...
D L, Simel +3 more
openaire +2 more sources
A 66-year-old man with the lupus anticoagulant-hypoprothrombinemia syndrome was treated with cyclophosphamide and prednisone to correct a factor II deficiency prior to elective major surgery. Whereas the lupus anticoagulant activity persisted, functional factor II levels normalized and he underwent surgery without a bleeding diathesis ...
D L, Simel +3 more
openaire +2 more sources
Seminars in Thrombosis and Hemostasis
Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is a rare, acquired coagulopathy syndrome. Here, we aim to summarize the clinical features of LAHPS to improve the understanding of the disease.
Bin Wang, Ning Tang, Chi Zhang
semanticscholar +1 more source
Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is a rare, acquired coagulopathy syndrome. Here, we aim to summarize the clinical features of LAHPS to improve the understanding of the disease.
Bin Wang, Ning Tang, Chi Zhang
semanticscholar +1 more source
Hypoprothrombinemia as a Complication of Propylthiouracil
JAMA, 1964PROPYLTHIOURACIL is of recognized value in the therapy of hyperthyroidism and the various adverse reactions to it have been thoroughly reviewed. Leukopenia and agranulocytosis are the most prominent hematologic reactions. In addition, purpura has been described.
openaire +2 more sources
ROTEM could be useful for lupus anticoagulant hypoprothrombinemia syndrome
Pediatrics InternationalLupus anticoagulant‐hypoprothrombinemia syndrome (LAHPS) is a rare disease caused by acquired factor II (FII) deficiency and lupus anticoagulant. Patients with LAHPS typically present with thrombosis and bleeding. However, little information is available
Koyo Yamada +5 more
semanticscholar +1 more source
The (reverse) paradox of lupus anticoagulant: A case report
LupusIntroduction Systemic Lupus Erythematosus (SLE) is often associated with antiphospholipid syndrome (APS), which manifests as recurrent thrombotic events or obstetric complications in presence of antiphospholipid antibodies.
Hiren Kalyani +4 more
semanticscholar +1 more source
Expert Opinion on Drug Safety
Background Aztreonam was approved by the FDA for treating Gram-negative infections, including metallo-β-lactamase producers. This study extensively evaluated aztreonam-related adverse events (AEs) from the FDA Adverse Event Reporting System (FAERS ...
Li-Li Cai +4 more
semanticscholar +1 more source
Background Aztreonam was approved by the FDA for treating Gram-negative infections, including metallo-β-lactamase producers. This study extensively evaluated aztreonam-related adverse events (AEs) from the FDA Adverse Event Reporting System (FAERS ...
Li-Li Cai +4 more
semanticscholar +1 more source